Table 1

Comparison of Baseline Characteristics Between the Elderly and Younger Groups

Age ≥75 yrs (n = 325)Age <75 yrs (n = 1,839)p Value
Age, yrs78.1 ± 2.760.5 ± 10.2<0.001
Male188 (58%)1,415 (77%)<0.001
Body weight, kg57.7 ± 11.266.8 ± 12.6<0.001
Body mass index, kg/m223.1 ± 3.924.3 ± 4.7<0.001
Duration of AF, yrs3.5 ± 5.33.9 ± 4.50.218
Paroxysmal AF238 (73%)1,235 (67%)0.030
Symptoms259 (80%)1.320 (72%)0.003
Medications
 No. of antiarrhythmic drugs0.8 ± 0.80.8 ± 0.80.517
 Antiplatelet drug58 (18%)214 (12%)0.002
Comorbidities
 Hypertension206 (63%)803 (44%)<0.001
 Diabetes mellitus55 (17%)247 (13%)0.094
 Heart failure59 (18%)235 (13%)0.009
 Stroke28 (8.6%)139 (7.6%)0.510
 History of maze procedure4 (1%)17 (1%)0.528
Echocardiographic data
 Left atrial diameter, mm40.3 ± 6.539.5 ± 6.80.047
 Left ventricular ejection fraction, %61.9 ± 9.760.6 ± 9.60.027
CHADS2 score2.2 ± 0.90.9 ± 1.0<0.001
CHA2DS2-VASc score3.7 ± 1.11.6 ± 1.4<0.001
HAS-BLED score2.0 ± 0.81.1 ± 1.0<0.001
Laboratory data
 Creatinine clearance, ml/min54.1 ± 17.789.4 ± 35.2<0.001
 B-type natriuretic peptide levels, pg/dl161.4 ± 283.388.7 ± 180.1<0.001
Ablation procedures
 Radiofrequency ablation275 (85%)1,564 (85%)0.841
 Repeat ablation115 (35%)554 (30%)0.059
Oral anticoagulant agents
 Dabigatran
  150 mg5 (1.5%)117 (6.4%)
  110 mg41 (13%)170 (9.2%)
 Rivaroxaban
  15 mg12 (3.7%)172 (9.4%)
  10 mg24 (7.4%)20 (1.1%)
 Apixaban
  5 mg52 (16%)411 (22%)
  2.5 mg37 (11%)41 (0.8%)
 Edoxaban
  15 mg3 (0.9%)20 (1.1%)
  10 mg12 (3.7%)19 (1%)
 Warfarin139 (43%)896 (49%)0.048
International normalized ratio2.0 ± 0.52.1 ± 0.60.379
Under the therapeutic range29 (21%)410 (46%)<0.001

Values are mean ± SD or n (%).

AF = atrial fibrillation; CHADS2 = congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, and stroke/transient ischemic attack; CHA2DS2-VASc = congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke/transient ischemic attack, vascular disease, age 65 to 74 years, and sex category; HAS-BLED = hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly, and drugs/alcohol concomitantly.

  • Twice daily.

  • Once daily.